Navigation Links
Tobira Therapeutics Inc. Announces Senior Management Team

- Senior management team possessing over 130 years of cumulative expertise


PRINCETON, N.J. and SAN DIEGO, June 30 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".

Dr. Palleja is the Chief Medical Officer, responsible for the overall clinical development of the Tobira Therapeutics portfolio. Sandra joined Tobira from Shionogi USA, where she lead numerous clinical programs as Vice President of Clinical Development in several therapeutic categories including an HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gained additional experience from both Triangle Pharmaceutics and Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to her career in industry, she was the Director of the Infectious Diseases Clinic at St. Vincent's Hospital and Medical Center of New York City during the mid to late 90's. Prior to her years at St. Vincent's, Sandra was an Associate Professor of Medicine, served as the Primary Care Liason to the AIDS Team at the Albert Einstein College of Medicine and Bronx Municipal Hospital Center. From 1989-1993, she also served as Consultant to the AIDS Institute, NYSDOH and the Federally Funded Ryan White Title III Program. She earned her MD from Boston University School of Medicine.

Ms. Shashlo joined Tobira from Incyte Corporation where she held a similar role as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte, Angie spent several years working with start-up companies such as Genaera, Vitagen and Ligand in a variety of roles including Project Management. Angeline spent many years working for larger pharmaceutical companies such as Wyeth and Upjohn during the first half of her 25-year career in positions of increasing responsibility. Angie received her Bachelor of Science in Pharmacy from the University of Michigan.

Dr. Rheingold brings over 29 years of experience in new product scale-up, formulation development and manufacturing to Tobira Therapeutics. Jay has successfully brought over 25 products to market during his tenure at Lederle, Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies. He received his doctorate in Pharmaceutical Sciences from the University of Connecticut. Jay joins Tobira from Barrier Therapeutics, where he held the position of Vice-President.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.


Tobira Therapeutics Inc.

James Sapirstein CEO and President Tobira Therapeutics, Inc.

Tel: 609-897-1102

SOURCE Tobira Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
5. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
6. Barrier Therapeutics to Merge Into Stiefel Laboratories
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
Breaking Biology Technology:
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... Research and Markets ( ) has ... Biometrics Market 2015-2019" report to their offering. ... global voice recognition biometrics market to grow at a ... --> --> The report, Global Voice ... an in-depth market analysis with inputs from industry experts. ...
(Date:10/22/2015)... (NASDAQ: SYNA ), a leading developer of human interface solutions, ... 2015. --> --> Net ... over the comparable quarter last year to $470.0 million. Net income ... $0.62 per diluted share. --> ... 2016 grew 39 percent over the prior year period to $56.9 ...
Breaking Biology News(10 mins):